Skye Bioscience (OTCMKTS:SKYE) Trading 14.1% Higher

Shares of Skye Bioscience, Inc. (OTCMKTS:SKYEGet Free Report) traded up 14.1% during trading on Friday . The stock traded as high as $1.74 and last traded at $1.74. 5,026 shares changed hands during trading, a decline of 19% from the average session volume of 6,196 shares. The stock had previously closed at $1.53.

Skye Bioscience Stock Up 14.1 %

The company’s 50-day moving average is $2.48 and its 200 day moving average is $0.90. The company has a market cap of $6.77 million, a price-to-earnings ratio of -0.16 and a beta of 0.91.

Skye Bioscience (OTCMKTS:SKYEGet Free Report) last released its quarterly earnings data on Monday, November 13th. The company reported ($3.17) earnings per share (EPS) for the quarter.

Skye Bioscience Company Profile

(Get Free Report)

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.

Featured Stories

Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with's FREE daily email newsletter.